Skip to main content

Table 3 Relationship between expression of total TNC, TNC-AD1 and TNC-AD2 and clinicopathological features of tumours

From: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women

Clinicopathological feature

 

Total TNC

TNC-AD1

TNC-AD2

 

n

Mean Ct (95% CI)

P

Mean Ct (95% CI)

P

Mean Ct (95% CI)

P

Age

       

   ≤40 years

47

23.5 (21.8 to 25.3)

0.006

36.6 (35.4 to 37.7)

<0.001

37.7 (36.7 to 38.6)

0.001

   >40 years

87

26.5 (25.7 to 27.3)

 

38.7 (38.1 to 39.3)

 

39.1 (38.5 to 39.7)

 

Tumour type

       

   IDC

109

25.4 (24.4 to 26.4)

0.554

37.8 (37.2 to 38.4)

0.079

38.7 (38.2 to 39.2)

0.760

   ILC

25

25.6 (24.7 to 26.5)

 

38.6 (37.1 to 40.0)

 

38.3 (36.5 to 39.9)

 

Grade

       

   I

14

27.6 (25.9 to 29.4)

0.109

39.1 (37.9 to 40.3)

0.017

39.8 (39.3 to 40.2)

0.066

   II

63

25.7 (24.6 to 26.7)

 

38.3 (37.4 to 39.1)

 

38.7 (37.9 to 39.5)

 

   III

57

24.7 (23.2 to 26.1)

 

37.3 (36.4 to 38.2)

 

38.2 (37.4 to 39.0)

 

Lymph node

       

   Positive

63

25.4 (24.2 to 26.6)

0.802

37.9 (37.2 to 38.8)

0.978

38.8 (38.2 to 39.4)

0.900

   Negative

68

25.5 (24.4 to 26.7)

 

37.9 (37.1 to 38.8)

 

38.5 (37.7 to 39.3)

 

   Not known

3

      

Oestrogen receptor

       

   Positive

89

25.6 (24.6 to 26.5)

0.413

38.2 (37.6 to 38.9)

0.011

38.7 (38.1 to 39.3)

0.316

   Negative

31

24.1 (22.2 to 26.1)

 

36.7 (35.3 to 38.0)

 

38.1 (36.9 to 39.3)

 

   Not known

14

      

Progesterone receptor

      

   Positive

79

25.4 (24.5 to 26.4)

0.431

37.9 (37.2 to 38.4)

0.441

38.8 (38.2 to 39.3)

0.641

   Negative

36

24.5 (22.6 to 26.4)

 

37.6 (36.4 to 38.7)

 

38.1 (36.8 to 39.5)

 

   Not known

19

      

Her-2

       

   Positive

17

23.3 (20.5 to 26.2)

0.232

37.6 (35.9 to 39.3)

0.639

38.2 (36.6 to 39.8)

0.452

   Negative

81

25.1 (24.2 to 26.1)

 

37.8 (37.0 to 38.6)

 

38.7 (38.0 to 39.4)

 

   Not known

36

      

Basal 1

       

   Positive

23

24.3 (22.2 to 26.4)

0.605

36.9 (35.3 to 38.6)

0.170

38.4 (37.2 to 39.7)

0.746

   Negative

109

25.4 (24.5 to 26.3)

 

38.0 (37.4 to 38.7)

 

38.6 (37.9 to 39.1)

 

   Not known

2

      

Basal 2

       

   Positive

22

25.8 (23.1 to 28.4)

0.103

37.6 (35.9 to 39.4)

0.960

38.5 (37.3 to 39.6)

1.000

   Negative

51

23.2 (21.4 to 25.0)

 

37.6 (36.6 to 38.7)

 

38.5 (37.7 to 39.3)

 

   Not known

61

      
  1. CI, confidence interval; Ct, number of cycles necessary to produce a product above background; IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular carcinoma; TNC, tenascin-C.